** Kura Oncology KURA.O shares jump 14% to $6.49 in pre-market trading
** KURA and Japan-based Kyowa Kirin 4151.T say the US FDA accepted marketing application for ziftomenib
** The drug, if approved, could be used to treat patients with acute myeloid leukemia, a type of blood cancer
** The disease affects about 22,000 people in the US every year, according to American Cancer Society
** Ziftomenib is a potential first-of-its-kind treatment for this aggressive form of leukemia, the cos say
** The FDA has granted priority review and is likely to decide by November 30 this year, they added
** YTD, stock down 34.7%, as of last close
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.